Highest-materiality recent filing
Agape ATP regains Nasdaq minimum bid price compliance; delisting hearing cancelled
Received Nasdaq notice on Mar 10, 2026, that bid price compliance restored under Rule 5550(a)(2).
Agape ATP announces 1-for-50 reverse stock split effective Feb 9, 2026
Reverse split ratio of 1-for-50; effective February 9, 2026; split-adjusted trading begins February 10, 2026 on Nasdaq.
Agape ATP receives Nasdaq delisting notice for low stock price; plans to appeal
Received delisting notice on Feb 2, 2026 under Low Priced Stocks rule (bid ≤ $0.10 for 10 days).
Agape ATP shareholders approve 60x increase in authorized shares and reverse split up to 1:5000
Authorized shares increased from 500M to 30B; approved with 30,073,422 for, 22,106 against.
Received Nasdaq notice Jan 27, 2026 for failing $1.00 minimum bid price based on closing bid Dec 10, 2025–Jan 26, 2026.
Agape ATP signs $24B supply agreements for jet fuel and diesel with Swiss One Oil & Gas
Aggregate SPA value approx $24B for 12-month supply of Jet Fuel A1 and EN590 diesel to Swiss One Oil & Gas AG.
Agape ATP closes $23M Reg S private placement; issues 46M shares at $0.50
Closed $23M private placement via issuance of 46M shares at $0.50/share to non-U.S. investors on March 24, 2025.
Agape ATP raises $23M private placement; 46M shares at $0.50, shares to increase 12.5x
Sold 46M shares at $0.50 each to 18 non-U.S. institutional investors under Regulation S for $23M.
Agape ATP partners with Formedic to launch LEGA respiratory care device
Collaboration agreement signed Sept 25, 2024, to introduce LEGA, an electronic chest percussion device for airway clearance.
Agape ATP regains Nasdaq minimum bid price compliance after 10 consecutive days above $1.00
Received Nasdaq notice on Sept 17, 2024 confirming compliance with $1 minimum bid price rule.
Agape ATP implements 1-for-20 reverse stock split, cuts authorized shares to 50M
Reverse stock split 1-for-20 effective August 30, 2024; authorized shares reduced from 1B to 50M.
Agape ATP fails to regain bid price compliance; Nasdaq delisting scheduled for July 30; will appeal
Received Nasdaq notice on July 19, 2024, for failing to regain minimum $1 bid price after 180-day period.
Agape ATP subsidiary ATPC Green Energy collaborates with B&H; B&H management gets 30% stake
ATPC Green Energy (wholly owned) signs Collaboration Agreement with B&H Intec Solution Sdn. Bhd.
Agape ATP dismisses Marcum Asia as auditor, hires Assentsure PAC
Board dismissed Marcum Asia CPAs LLP effective April 25, 2024; no disagreements on accounting principles or practices.
Agape ATP regains Nasdaq compliance on minimum equity rule after deficiency notice
Received March 28 deficiency letter for failing MVLS of $35M under Rule 5550(b)(2).
Agape ATP receives Nasdaq MVLS deficiency notice; 180 days to regain compliance
Nasdaq notified Agape ATP on March 28, 2024 that MVLS fell below $35M minimum from Feb 14 to Mar 27, 2024.
Agape ATP receives Nasdaq bid price deficiency notice; faces potential delisting
Nasdaq notified Agape ATP on Jan 18, 2024, that its bid price closed below $1 for 30 consecutive trading days.
CEO Dr. How Kok Choong's salary amended from $0 to $400,000 per annum
Compensation amendment for CEO Dr. How Kok Choong approved December 28, 2023.
Agape ATP closes IPO of 1.65M shares at $4.00; warrants for 115,500 shares
Closed IPO of 1,650,000 common shares at $4.00 per share on October 13, 2023.
Agape ATP corrects share forfeiture date; 215M shares cancelled in Feb 2022
CEO How Kok Choong forfeited 215,008,035 shares of common stock pursuant to agreement dated January 20, 2022.
Agape ATP CEO forfeits 215M shares, reducing outstanding count
How Kok Choong forfeited 215,008,035 shares to the company on Feb. 28, 2022.
Agape ATP cancels 86.99M shares via forfeiture agreements with HKC Talent and other shareholders
HKC Talent Limited forfeited 41,750,000 shares of common stock.
On November 15, 2024, Ms. Rose Marie Kadende Kaiser, PhD (“Ms. Rose, PhD) was appointed as an independent director of the Board to fill the vacancy left by Dr Vong, PhD’s resignation.
Dr. Vong, PhD will serve as the Deputy Chairman of the Board following his resignation effective on the same day.
On October 1, 2024, Mr. Chee Chin Aik (“Mr. Chee”) resigned as our independent director of the Board of Directors (the “Board”), the chairman of the nominating and governance committee and as a member of the audit and compensation committees of the Agape ATP Corporation (the “Company”), effective from October 1, 2024.
On October 1, 2024, Dr. Ni Luh Dharma Kerti Natih (Dr. Natih) was appointed as an independent director of the Board to fill the vacancy left by Mr. Chee’s resignation.
elected Dr. Wilfrendo Fernando Cortizo, Phd (Dr. Cortizo) as a director of the Board.
Mr. Mohd Shaharuddin Bin Abdullah resigned from the Company as an executive director and his employment agreement terminated with immediate effect.
Mr. Tjong Budisantoso, Phd ("Mr. Budisantoso, Phd") was appointed as an executive director to fill the vacancy, effective on the listing of our stock on Nasdaq Capital Market.
On March 30, 2022, Mr. Ramesh Ruben Louis, Phd (“Mr. Louis, Phd”) was appointed as an independent director of the board of directors (the “Board”) of Agape ATP Corporation (the “Company”), effective upon the Company’s initial public offering on the NASDAQ Stock Market/The New York Stock Exchange.
On March 30, 2022, Mr. Ramesh Rubin Louis, Phd (“Mr. Louis, Phd”) was appointed as an independent director of the board of directors (the “Board”) of Agape ATP Corporation (the “Company”), effective upon the Company’s initial public offering on the NASDAQ Stock Market/The New York Stock Exchange.
Max materiality 0.90 · Median 0.55 · Most common event other_material